文献速递神经肿瘤

图卡替尼联合立体定向放射外科治疗HER2阳性乳腺癌脑转移

Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases.
PubMed 文献 · J Neurooncol · 2023-07-25

该回顾性分析纳入22例接受图卡替尼联合立体定向放射外科(SRS)治疗的HER2阳性乳腺癌脑转移患者,共135个病灶、39次治疗。12个月和24个月局部脑控制率分别为94%和81%,中位生存期21.2个月,症状性放射性坏死6个(4%)病灶。作者认为该联合方案安全可行,但需进一步前瞻性评估。

要点

  • 图卡替尼联合SRS治疗HER2阳性乳腺癌脑转移,12个月局部脑控制率94%,24个月81%。
  • 中位随访20.8个月,中位生存期21.2个月,12个月和24个月OS率分别为84%和50%。
  • 症状性放射性坏死发生于6个(4%)病灶,未见其他意外毒性。

核心结论

  • SRS联合图卡替尼、卡培他滨和曲妥珠单抗似乎是HER2阳性脑转移安全且可行的治疗方式。
  • 需进一步前瞻性评估潜在协同效应。

研究设计与样本

  • 回顾性分析HER2阳性乳腺癌接受SRS联合图卡替尼治疗脑转移的患者。
  • 所有患者均接受图卡替尼和SRS治疗活动性脑转移。
  • 共纳入22例患者,135个病灶,39次治疗。
  • 主要终点为局部和远处脑肿瘤控制,次要终点包括颅内无进展生存期(CNS-PFS)、全身PFS、总生存期(OS)和神经毒性。

主要发现

  • 中位随访自图卡替尼启动起为20.8个月。
  • 局部脑控制12个月为94%,24个月为81%。
  • 远处脑控制12个月为39%,24个月为26%。
  • 中位生存期21.2个月,12个月和24个月OS率分别为84%和50%。
  • 中位CNS-PFS为11.3个月,12个月和24个月CNS-PFS率均为44.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: HER2-positive breast cancer has a high risk of brain metastasis. Stereotactic radiosurgery (SRS) is standard of care for limited brain metastases. Tucatinib, a HER2-targeted tyrosine kinase inhibitor, has demonstrated intracranial efficacy in the HER2-CLIMB Trial. However, it is unknown whether tucatinib with SRS is safe or effective. METHODS: A retrospective analysis of HER2-positive breast cancer treated with SRS and tucatinib for brain metastases management was performed. All patients received tucatinib and SRS for the management of active brain metastases. The primary endpoint was local and distant brain tumor control. Secondary endpoints were intracranial progression free survival (CNS-PFS), systemic PFS, overall survival (OS), and neurotoxicity. RESULTS: A total of 135 lesions treated with SRS over 39 treatment sessions in 22 patients were identified. Median follow-up from tucatinib initiation was 20.8 months. Local brain control was 94% at 12-months and 81% at 24-months. Distant brain control was 39% at 12-months and 26% at 24-months. Median survival was 21.2 months, with 12- and 24-month OS rates of 84% and 50%, respectively. Median CNS-PFS was 11.3 months, with 12- and 24-month CNS-PFS rates of 44.9% at both time points. Median systemic PFS was not reached, with 12- and 24-month systemic PFS rates of 86% and 57%, respectively. Symptomatic radiation necrosis occurred in 6 (4%) lesions. No additional unexpected toxicities were noted. CONCLUSIONS: SRS in combination with tucatinib, capecitabine, and trastuzumab appears to be a safe and feasible treatment for HER2 + brain metastases. Further prospective evaluation of potential synergistic effects is warranted.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Khatri VM, Mills MN, Oliver DE, et al. Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases. J Neurooncol. 2023. PMID: 37490232. doi:10.1007/s11060-023-04402-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。